Novavax (NVAX) Upgraded to Buy: Here's What You Should Know

Novavax (NVAX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research • Feb 23, 2026

What's in Store for These 5 Medical Companies This Earnings Season?

IRWD, RXRX, NVAX, VTRS and NTLA gear up for earnings as the Medical sector posts solid sales growth despite a slight profit dip so far.

Zacks Investment Research • Feb 23, 2026

Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

GAITHERSBURG, Md., Feb. 19, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its fourth quarter and full year 2025 financial results and operational highlights at 8:30 a.m.

PRNewsWire • Feb 19, 2026

Is Most-Watched Stock Novavax, Inc. (NVAX) Worth Betting on Now?

Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.

Zacks Investment Research • Feb 17, 2026

Novavax (NVAX) Rises As Market Takes a Dip: Key Facts

Novavax (NVAX) reached $8.97 at the closing of the latest trading day, reflecting a +2.51% change compared to its last close.

Zacks Investment Research • Feb 11, 2026

Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know

Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks Investment Research • Feb 6, 2026

Why Novavax (NVAX) Dipped More Than Broader Market Today

Novavax (NVAX) concluded the recent trading session at $8.37, signifying a -3.68% move from its prior day's close.

Zacks Investment Research • Feb 3, 2026

Moderna Vs. Novavax: 2 Pandemic Vaccine Pioneers - Which Offers Better Value Today?

Moderna, Inc. and Novavax, Inc. have transitioned from pandemic-era highs to focusing on cost reduction, pipeline development, and a path to breakeven by 2028. NVAX leverages partnerships with Sanofi and Pfizer, targeting ~$500m annual revenues by 2030, with a forward P/S of ~3x and P/E of ~7.5x. MRNA's growth depends on COVID/flu combo vaccine, intismeran cancer program, and RSV vaccine, but faces higher risk due to elevated spending and lack of major partners.

Seeking Alpha • Jan 30, 2026

This Beaten-Down Biotech Is Showing Signs of Life. Is It a Buy?

Novavax signed a potentially lucrative deal with a pharmaceutical giant. However, the biotech's core business remains uncertain.

The Motley Fool • Jan 29, 2026

Here's Why Novavax (NVAX) Fell More Than Broader Market

In the latest trading session, Novavax (NVAX) closed at $9.22, marking a -6.07% move from the previous day.

Zacks Investment Research • Jan 28, 2026